TY  - JOUR

T1  - Implications and benefits of the NICE appraisal of pembrolizumab

JO  - British Journal of Healthcare Management

UR  - https://doi.org/10.12968/bjhc.2015.21.11.506

PY  - 2015/11/02

AU  - Danson S

ED  - 

DO  - DOI: 10.12968/bjhc.2015.21.11.506

PB  - Mark Allen Group

VL  - 21

IS  - 11

SP  - 506

EP  - 508

Y2  - 2025/12/07

ER  -